Clinical Sales Representative

Noah Medical announces galaxy(tm) II. 11th, August 2026 2 mins read Noah Medical has announced the commercial launch of the Galaxy II software, the next evolution of the company's robotic-assisted bronchoscopy (RAB) platform. The Galaxy II software gives physicians imaging flexibility and procedural control to take on their most complex cases with confidence, advancing what bronchoscopy can deliver across every dimension of the procedure. Lung cancer remains the leading cause of cancer death worldwide, and survival depends heavily on early diagnosis, making the ability to accurately biopsy small, hard-to-reach lung lesions one of the most consequential steps in a patient's path to treatment. At the center of the system is Dual-Mode Imaging, which lets physicians move seamlessly between Galaxy's High- Definition Digital Tomosynthesis (HD-DT) and Cone-Beam CT (CBCT) at any point in a procedure. HD-DT delivers efficiently and effectively across the vast majority of cases at a fraction of the radiation dose, while CBCT is available at the moment a case calls for more. The result puts the imaging decision where it belongs, in the physician's hands. "Galaxy II software puts physicians in control of their imaging strategy for every procedure," said Jian Zhang, founder and CEO of Noah Medical. "By bringing HD-DT, CBCT, and advanced robotic control together in one platform using the Galaxy II software, we let physicians choose what each case requires, enabling them to adapt to each patient's anatomy and reduce radiation exposure while maximizing procedural efficiency." Accurately reaching and sampling small pulmonary lesions remains difficult due to two persistent challenges: CT-to-Body Divergence, where the preoperative CT no longer matches the patient's anatomy during the procedure, and Tool-Tissue Divergence, where a biopsy tool drifts from its intended path even when the catheter is well positioned. Galaxy II software addresses both by uniting navigation, imaging, and real-time confirmation of the lesion and tool in a single platform. "The Galaxy System's unique ability to correct for tool-tissue divergence in real time drives its high diagnostic yield, giving physicians confidence that their biopsy tool is exactly where they intend it," said Dr. Francisco Almeida, Interventional Pulmonologist at City of Hope(R) Cancer Center Atlanta. "Galaxy II software builds on that foundation, enhancing navigation, imaging, and confirmation in a single platform. It puts the choice of imaging modality in the physician's hands, so procedures run more efficiently while also cutting the radiation burden on patients and clinicians."

Noah Medical has launched Galaxy II software for its robotic-assisted bronchoscopy platform. The system features Dual-Mode Imaging, allowing physicians to switch between High-Definition Digital Tomosynthesis and Cone-Beam CT during procedures. The technology addresses challenges in biopsying small lung lesions by combining navigation, imaging, and real-time confirmation in one platform. HD-DT provides imaging at up to 10 times lower radiation dose than CBCT for most cases, whilst CBCT remains available for complex procedures. The Galaxy System demonstrated 96.7% diagnostic yield in the multicentre MATCH II study and 90% yield in routine clinical practice at Cleveland Clinic across 100 consecutive patients. Lung cancer remains the leading cause of cancer death worldwide, with survival heavily dependent on early diagnosis.